Amylin based therapies are emerging as promising obesity medications. , Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! , Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications Eli Lilly Comes Out As ADA Winner (NYSE:LLY) Seeking Alpha Eli Lilly's Eloralintide Phase 2 Trial shows up to 20% Weight Loss with Promising Tolerability in Adults with Obesity Pharmacally PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar